Therapeutic effect evaluation of leonurine,polygonatum polysaccharide and deoxynojirimycin in combination on antithrombosis and hypoglycaemia
- Author:
Zi-Li WANG
1
;
Zhu-Nan GONG
1
;
Shu-Wen XU
2
;
Hui ZHAO
2
;
Jin-Huan BIAN
3
;
Zhu-Nan GONG
3
Author Information
- Publication Type:Journal Article
- Keywords: deoxynojirimycin; diabetes; leonurine; polygonatum polysaccharide; thrombosis; zebrafish
- From: Chinese Pharmacological Bulletin 2023;39(1):139-146
- CountryChina
- Language:Chinese
- Abstract: Aim To evaluate the efficacy of the combination of leonurine(SCM),polygonatum polysaccharide(PSP)and deoxynojirimycin(DNJ)in hypoglycemic and antithrombotic aspects by establishing and using zebrafish type II diabetes combined with thrombosis model. Methods On the basis of the zebrafish type II diabetes model established by streptozotocin,phenylhydrazine(PH),arachidonic acid(AA)and ponatinib(PT)were used respectively to establish thrombosis models,which were divided into control group,model group,metformin+aspirin group,and the high,medium and low concentration groups of the combination drugs. After drug intervention in the experimental group,the thrombosis of tail vein was observed. Kit was used to determine the sugar content of juvenile fish tissues in each group. Quantitative analysis of cardiac erythrocytes by o-dianisidine staining method was used to calculate the inhibition rate of thrombus. Quantitative real-time polymerase chain reaction(qRT-PCR)was used to detect the mRNA expressions of related genes in zebrafish. Results Compared with the model group,the combined drug could significantly increase the staining intensity of erythrocytes in zebrafish hearts,inhibit thrombosis,down-regulate the expression of thrombosis-related genes,and reduce tissue glucose content. Conclusions The combined use of the three drugs can effectively reduce the tissue sugar content and have antithrombotic effect,which show great potential in the development of drugs for the treatment of type II diabetes and thrombosis.
